Highly profitable, high-growth telemedicine platform serving the German medical cannabis market

Unique opportunity to acquire a rapidly scaling, fully remote telemedicine and digital prescription, GDPR-compliant platform operating under the EU cross-border framework. The business connects over 20,000 patients with licensed doctors and pharmacies in Germany

Operates under EU cross-border telemedicine framework (Physicians licensed in Germany & Poland). GDPR-compliant platform. No direct cannabis handling license required.

• Cyprus-based company operates a fully digital telemedicine platform, enabling remote consultations and digital prescriptions

• Launched in 2024, the platform has served approximately 20,000 patients and processed over 6,500 prescriptions per month

• Focused on deep process optimization to ensure scalability before launching targeted marketing campaigns, including Facebook advertising and affiliate marketing, and continues to implement new features to enhance user experience

• Profitable business with margins exceeding 60%, a current revenue run rate of ~€140,000 per month, and a forecasted €1.5M by year-end, reflecting ~20% annual growth

• Income is generated through patient appointment bookings, marketing services for pharmacies, partnerships with leading producers, and white-label product offerings.

• Operates efficiently with ~12 staff/freelancers, leveraging front-end and back-end freelance specialists

• Automated workflows reduce doctor consultation time by 90%, and the platform supports white-label functionality for rapid B2B expansion

• Projected annual growth of 15–20% is driven by rising patient demand and recent liberalization of the German cannabis market

• Seeking full sale and includes the going concern business, intellectual property, brand, patient database, and software codebase